136 results on '"Mu, Zhaomei"'
Search Results
2. Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
3. Data from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
4. Supplementary Figure S1: Edelfosine and ADT inhibits cell proliferation in VCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
5. Supplementary Figure S3: Temporal expression of p-AKT after AD and edelfosine treatment in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
6. Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
7. Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
8. Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
9. Supplementary Figure Legends from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
10. Table S1 from Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells
11. Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
12. Data from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
13. Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
14. Supplementary Table S1. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
15. Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
16. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer
17. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
18. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer
19. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study
20. Presence of anaplastic lymphoma kinase in inflammatory breast cancer
21. Inflammatory breast cancer (IBC): clues for targeted therapies
22. Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell–Cell Interactions in Tumor Progression
23. PKA knockdown enhances cell killing in response to radiation and androgen deprivation
24. Antisense MDM2 Enhances the Response of Androgen Insensitive Human Prostate Cancer Cells to Androgen Deprivation In Vitro and In Vivo
25. Antisense Bcl-2 Sensitizes Prostate Cancer Cells to Radiation
26. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
27. Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration
28. Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog).
29. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
30. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
31. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells
32. Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells
33. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
34. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
35. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
36. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
37. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
38. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).
39. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.
40. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
41. Abstract 3232: CEP-37440, a highly selective and potent dual inhibitor of ALK and FAK1 inhibits the proliferation of inflammatory breast cancer cells
42. Abstract 2788: Comprehensive high-depth target sequencing in circulating tumor DNAs of patients with inflammatory and non-inflammation breast cancers
43. Abstract 384: Detection of circulating melanoma cells in paired arterial and venous specimens from uveal melanoma patients with hepatic metastatic
44. Abstract 224: Enrichment and isolation of uncontaminated breast cancer cells from human blood samples
45. Abstract P4-01-11: Circulating tumor cells (CTCs) detect HER2+ status and phenotypic heterogeneity in metastatic breast cancer (MBC)
46. Abstract P6-14-06: CCR5 antagonists suppresses the migration and invasion of human inflammatory breast cancer cells
47. Abstract P4-01-20: A novel microfluidic system for the detection, enumeration and molecular analysis of circulating tumor cells (CTCs) in metastatic breast cancer (MBC)
48. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
49. Abstract 4988: Clues for targeted therapies in inflammatory breast cancer (IBC)
50. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.